UCL School of Pharmacy
- About the School
- Study Here
- Master of Pharmacy (MPharm)
- MSc in Clinical Pharmacy, International Practice and Policy
- MSc in Drug Delivery
- MSc in Drug Discovery and Development
- MSc in Drug Discovery and Pharma Management
- MSc in Pharmacognosy
- MSc Experimental Pharmacology and Therapeutics
- Master of Research (MRes)
- Research Areas
- How to apply
- Entry requirements
- Tuition Fees
- PhD Studentships
- Next-generation sequencing in inhibitory synaptic disorders
- Nanoparticle self-association from inhaled microparticles
- Understanding the role of Ca2+ currents in influencing neuronal activity in entorhinal cortical neurons.
- Understanding the mechanisms of hyposmia in a novel model of early stage Parkinson's Disease (ESPD) and its reversal by exendin-4
- Structure-function studies of defective excitatory and inhibitory transmission in neurological disease
- New methods for exquisite control and quantification of amorphous pharmaceuticals
- High-throughput discovery of novel nanoparticulate vaccine adjuvants for humans
- Development of novel formulations to improve skin health
- The Development of Electrospun Nanofibrous Matrices for the Oral Delivery of Poorly Water Soluble Therapeutic Agents
- Scholarships & funding
- Pharmacy Practice (PG Dip/MSc)
- Certificate in Medicines Management for Pharmacy Technicians
- Research Themes
- News Archive
- Student Life
- International students
- Library and Services
- Research Departments
- Work Here
- Contact Us
- UCL School of Pharmacy News
Synapses releasing the neurotransmitters GABA, glycine and glutamate play essential roles in health and disease, with defects in synaptic and tonic inhibition resulting in diseases such as autism, idiopathic generalised epilepsies, intellectual disability and startle disease. With the advent of high-throughput exome and genome sequencing technologies, numerous rare sequence variants not present in the general population are being discovered and often published with very little in the way of functional validation to prove pathogenicity. This project will integrate new approaches for testing novel sequence variants found in genes encoding pre- and post-synaptic components of inhibitory and excitatory synapses (e.g. ligand-gated ion channels, neurotransmitter transporters, clustering proteins) using bioinformatics, molecular modelling, molecular biology and electrophysiological assays.
The PhD student will be jointly supervised by Professor Robert J Harvey at UCL School of Pharmacy and Professor Trevor G Smart from the UCL Research Department of Neuroscience, Physiology & Pharmacology. The successful candidate will receive cross disciplinary training in molecular biology, cellular biochemistry, molecular modelling, imaging methods and electrophysiology. The supervisors have an extensive collaborative track record in structure-function studies of ligand-gated ion channels and neurotransmitter transporters (e.g. Harvey et al 2004, Science 304:884-887; Rees et al 2006, Nat Genet 38:801-806; Manzke et al 2010, J Clin Invest 120:4118-4128).
Main methods and techniques to be employed
The PhD student will be trained in how to generate expression constructs, conduct site-directed mutagenesis, structural homology modelling of receptors and/or transporters, perform bioinformatics analysis (SIFT, PolyPhen) and prioritise mutations for further modelling and functional assays.
This studentship is limited to students with Home/ EU
tuition fee status and the preferred start date is October 2013.
The successful applicant will be expected to have a UK Bachelor’s degree in Pharmacy, Pharmacology, Biology, Biochemistry, Molecular Biology or Genetics, awarded with first or upper second-class Honours, or an overseas qualification of an equivalent standard from a recognised higher education institute, or a recognised taught Master’s degree is required.
include CV, personal statement plus the contact details of two referees and
should be sent to Victor Diran.
For any academic queries please contact the lead supervisor Prof Robert J Harvey.
Closing date of application is 30th April 2013.
Page last modified on 27 mar 13 18:06